We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mutation Patterns of DNA Repair Enzymes May Foretell Pancreatic Cancer Risk

By LabMedica International staff writers
Posted on 28 Jan 2009
Cancer researchers have found that the pattern of mutations in genes that produce DNA repair enzymes may be used to foretell increased or decreased risk of developing pancreatic cancer, depending on the genes involved.

As pancreatic cancer is often identified in late stages when it is resistant to most available therapies, there is considerable interest in characterizing genetic profiles that could be used to identify high-risk individuals for the purpose of prevention and early detection of this disease. More...


Toward this end, investigators at the University of Texas M. D. Anderson Cancer Center (Houston, USA) analyzed nine single nucleotide polymorphisms of seven DNA repair genes (LIG3, LIG4, OGG1, ATM, POLB, RAD54L, and RECQL) in 734 patients with pancreatic cancer and 780 healthy controls using the Taqman PCR (polymerase chain reaction) method for amplifying DNA expression. Information on cigarette smoking, alcohol consumption, medical history, and other risk factors was collected by personal interview. They reported in the January 15, 2009, issue of the journal Clinical Cancer Research that the presence of a homozygous mutant genotype of LIG3 G-39A was associated with a 77% reduction in the risk of pancreatic cancer. By contrast, the presence of the gene ATM D1853N was associated with a nearly threefold (255%) increased risk of pancreatic cancer.

"Currently, there is no approved genetic screening tool for pancreatic cancer," said first author Dr. Donghui Li, associate professor of gastrointestinal medical oncology at the M. D. Anderson Cancer Center. "Our study provides some preliminary data on one pattern of genetic variations that may be useful in determining risk. However, we still need to be cautious. As with any science, the key is replication, and the results of this study need to be confirmed by others."

Related Links:

University of Texas M. D. Anderson Cancer Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.